Santoli's Tuesday market wrap-up: Market back on its heels after weak ISM services report
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Retail spending jumps in July
You can find original article here Supermarketnews. Subscribe to our free daily Supermarketnews newsletter. Consumers took advantage of summer sales promotions in July to buy goods before new tariffs on imports took effect this month, according to a report from the National Retail Federation. Total retail sales, excluding automobiles and gasoline, were up a seasonally adjusted 1.45% month over month, compared with a decrease of 0.33% in June. On an unadjusted, yearly basis, sales were up 5.93%, compared with an increase of 3.19% in June. The gains were the biggest monthly increase since the CNBC/NRF Retail Monitor began tracking retail sales in 2022. 'We may be seeing growing inflationary impacts from tariffs since recent data shows price increases in commodity goods, particularly non-durables,' said Mathew Shay, president and CEO, NRF. 'Even with weaker job growth than many expected, consumers still have the ability to spend on household priorities as wages are growing above the rate of inflation.' He was referring to the July jobs report from the Bureau of Labor Statics, which showed that the U.S. added 73,000 jobs in July and the unemployment rate rose slightly, to 4.2%, from 4.1% in June. Economists had expected job growth of at least 100,000, according to reports. The BLS also revised its job growth down sharply for May and June. Grocery, beverage store sales up 1.43% Sales at grocery and beverage stores were up 1.43% on a seasonally adjusted, month-to-month basis in July and were up 5.42% year-over year on an unadjusted basis, according to the NRF report. In June, the NRF report found that sales at grocery and beverage stores were down 0.13% on a seasonally adjusted, monthly basis, and up 2.59% year-over-year, unadjusted. The CNBC/NRF Retail Monitor report, powered by Affinity Solutions, tallies real credit card spending, unlike the survey data used by the Census Department, which is expected to release its July retail sales report this Friday. The government's monthly Consumer Price Index and Producer Price Index for July are also expected this week. The NRF July retail sales data got a boost from several big retail sales events, including Amazon Prime Day, Walmart Deals, Target Circle Week, and other mid-summer promotions, according to reports. 'There is some tariff inflation bleeding through,' said Steve Liesman, senior economics reporter, CNBC, in a report on the NRF data. 'It's a very mixed picture, and it's very choppy.' ** Download the Supermarket News media kit here Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today
Key Points Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P 500 index fund. Still, Pfizer today offers a fat dividend and plenty of growth potential. 10 stocks we like better than Pfizer › Wondering how well you'd have done if you'd invested in pharmaceutical giant Pfizer (NYSE: PFE) three years ago and hung on? Well, I'm afraid the answer isn't pretty: If you'd investing $1,000 in Pfizer on Aug. 8, 2022, hung on and reinvested dividends, that sum would have been worth $585 on Aug. 8, 2025. Ouch! For some context, during those same three years, the S&P 500 index of 500 of America's biggest companies averaged gains of roughly 17% per year, turning $1,000 into $1,615. Here's some good news, though: Stock investors need to look forward much more than backward. Trailing returns are in the past. What matters most for current Pfizer investors and would-be Pfizer investors is how the company will perform from here on. And Pfizer's future is looking promising. Some investors have been disappointed in Pfizer when they've compared recent results to those from the past. But those past years were exceptional boom years thanks to Pfizer's COVID-19 vaccine and Paxlovid COVID-19 treatment. Those were in great demand, but demand has fallen. Others worry because some of Pfizer's big sellers, such as Eliquis, Ibrance, Inlyta, Xeljanz, Xtandi, and Vyndaqel, are coming off patent protection in the next few years. Pfizer has been planning for that, and investing in its pipeline, which features more than 100 active programs -- many of which are in oncology. Pfizer has also been getting additional approvals for its drugs, and it has been cutting its costs in an effort to boost profitability. Finally, Pfizer is a dividend-paying stock, with a whopping recent dividend yield of 7%. So as you invest in Pfizer and wait for its investments to pay off, you'll be rewarded. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Selena Maranjian has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
CNBC
2 hours ago
- CNBC
CNBC Daily Open: Investors seem conditioned to expect Trump reversals
The heaviest of U.S. President Donald Trump's "reciprocal" tariffs — a full 145% on imports of Chinese goods — was, once again, delayed for another 90 days. The move should be a huge relief not just to investors, but perhaps most of the population on Earth. The U.S. and China are the two largest economies in the world, according to World Bank data, and a trade war in which imports of each other's goods double in price would probably stymie, if not cripple, the global economy. But markets were mostly unmoved. Well, they did move — lower. The three big U.S. stock indexes retreated Monday as this outcome was more or less expected, since both sides had earlier telegraphed an extension of the tariff pause. Investors could have also been conditioned to expect flip-flopping from Trump, such that threats, promises, criticisms and praises don't carry as much heft as they should anymore. On Monday, Trump said Intel's CEO Lip-Bu Tan's "success and rise is an amazing story," after describing Tan as "highly CONFLICTED" the week before. There's a Freudian idea in which an individual projects their thoughts and feelings to another person. Researchers are, well, conflicted, on the veracity of the phenomenon, but empirical observation suggests it's not uncommon. Trump extends pause on China tariffs. U.S. tariffs on China were delayed for 90 days, Trump said on Truth Social. It was the expected outcome from the latest round of talks between the two countries. E.J. Antoni to be nominated as Bureau of Labor Statistics commissioner. Trump said Monday that Antoni, the chief economist at the conservative Heritage Foundation, is his choice to replace Erika McEntarfer, whom he fired after accusing her of data manipulation. Intel CEO is a "success," Trump says. The U.S. president's praise of Lip-Bu Tan is a reversal in tone from his previous week's message, in which Trump said Tan "must resign, immediately." U.S. stocks end Monday lower. Major stock indexes fell as traders awaited the release of the consumer price index later today — and appeared unimpressed by Trump's extension of tariff truce with China. European markets dipped as well. [PRO] Citibank raises its S&P 500 forecast. The Wall Street bank attributed its higher year-end target for the index to strong quarterly earnings, expected benefits from Trump's One Big Beautiful Bill and a better-than-expected impact from tariffs. What Trump's Nvidia and AMD China deal means for the world Nvidia and AMD have agreed to share some of their revenue from sales to China with the U.S. government, according to several reports. The arrangement crafted by U.S. President Donald Trump's administration is "unusual," analysts told CNBC, but underscores the transactional nature of the current White House leader. Meanwhile, investors see the move as broadly positive for both Nvidia and AMD, which can again secure access to the Chinese market.
